Saturday 17 October 2026
Export IXHL’s income statement to Excel — free account
Incannex Healthcare Inc.
IXHL Healthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024. In the quarter to June 2026, revenue fell 92.3%, EPS grew 99.0% and free cash flow grew 327.7%, each against the same quarter a year earlier.
2.82
0.06
−2.08%
Follow IXHL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(114.52%) | (130.42%) | (117.17%) | (47.80%) | |
| (101.03%) | (112.64%) | (100.36%) | (41.32%) | ||
ROIC |
(407.88%) | (390.46%) | (2,022.08%) | 0.00% | |
Return on Tangible Assets |
(62.32%) | (66.22%) | (61.90%) | (27.06%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.88) | (1.58) | (1.44) | (1.10) | |
Free Cash Flow |
(19.44) | (18.43) | (17.73) | (12.88) | |
Capital Expenditures |
(0.01) | (0.01) | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(12.94%) | (12.93%) | (11.85%) | (9.53%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.41 | 0.38 | 0.37 | 0.67 | |
Depreciation/Fixed assets |
1.48 | 1.68 | 5.34 | 60.00 | |
Capex/Depreciation |
(0.04) | (0.03) | (0.04) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.88) | (1.58) | (1.44) | (1.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Oct 2026